Tumor-Specific Low Molecular Weight Forms of Cyclin E Induce Genomic Instability and Resistance to p21, p27, and Antiestrogens in Breast Cancer

Cancer Research

Volumn 64, Issue 9, 2004, Pages 3198-3208

  Akli, Said ^a   Zheng, Ping Ju ^a   Multani, Asha S ^a   Wingate, Hannah F ^a,b   Pathak, Sen ^a   Zhang, Ning ^a   Tucker, Susan L ^a   Chang, Sandy ^a   Keyomarsi, Khandan ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; PROTEIN P21; PROTEIN P27;

ADULT; AGED; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER HORMONE THERAPY; CONTROLLED STUDY; CYTOGENETICS; GENE OVEREXPRESSION; GENETIC STABILITY; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MAJOR CLINICAL STUDY; MOLECULAR MECHANICS; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BREAST NEOPLASMS; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; G1 PHASE; GENOMIC INSTABILITY; HUMANS; MIDDLE AGED; MOLECULAR WEIGHT; POLYPLOIDY; PROTEIN ISOFORMS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 2342593373     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3672     Document Type: Article

References (38)

1. Sherr CJ. Cancer cell cycles. Science (Wash. DC) 1996;274:1672-7.
2. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 1993;90:1112-6.
3. Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8:2127-33.
4. Koepp DM, Schaefer LK, Ye X, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science (Wash. DC) 2001;294:173-7.
5. Porter DC, Zhang N, Danes C, et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001;21:6254-69.
6. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994;54:380-5.
7. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
8. Keyomarsi K, Tucker SL, Bedrosian I. Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med 2003;9:152.
9. Harwell RM, Porter DC, Danes C, Keyomarsi K. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 2000;60:481-9.
10. Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle 2003;2:461-6.
11. Stighall M, Berglund P, Landberg G. Lower molecular weight forms of cyclin E: super activators of the cell cycle? Cell Cycle 2003;2:458-60.
12. 1 in mammalian fibroblasts. Science (Wash. DC) 1993;259:1908-12.
13. 1-S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994;14:1669-79.
14. Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 1997;17:453-9.
15. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature (Lond.) 1999;401:297-300.
16. Won KA, Reed SI. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J 1996;15:4182-93.
17. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 1996;10:1979-90.
18. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein bCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature (Lond.) 2001;413:316-22.
19. Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK. Archipelago regulates cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature (Lond.) 2001;413:311-6.
20. Spruck CH, Strohmaier H, Sangfelt O, et al. hCDC4 gene mutations in endometrial cancer. Cancer Res 2002;62:4535-9.
21. 1-S phase transition. Mol Cell Biol 1995;15:2612-24.
22. 1 cyclin (Cln) function in yeast. Cell 1991;66:1197-206.
23. Koff A, Cross F, Fisher A, et al. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 1991;66:1217-28.
24. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci USA 1996;93:15215-20.
25. 1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998;17:2393-402.
26. Pathak S. Chromosome banding techniques. J Reprod Med 1976;17:25-8.
27. LaBaer J, Garrett MD, Stevenson LF, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997;11:847-62.
28. Cheng M, Olivier P, Diehl JA, et al. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999;18:1571-83.
29. Planas-Silva MD, Weinberg RA. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 1997;17:4059-69.
30. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 1997;272:10882-94.
31. Skildum AJ, Mukherjee S, Conrad SE. The cyclin-dependent kinase inhibitor p21WAF1/Cip1 is an antiestrogen-regulated inhibitor of Cdk4 in human breast cancer cells. J Biol Chem 2002;277:5145-52.
32. Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature (Lond.) 1996;382:325-31.
33. Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 1999;287:821-8.
34. Chang S, Khoo C, DePinho RA. Modeling chromosomal instability and epithelial carcinogenesis in the telomerase-deficient mouse. Semin Cancer Biol 2001;11:227-39.
35. O'Hagan RC, Chang S, Maser RS, et al. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell 2002;2:149-55.
36. Hui R, Finney GL, Carroll IS, Lee CS, Musgrove EA, Sutherland RL. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res 2002;62:6916-23.
37. Dhillon NK, Mudryj M. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 2002;21:4626-44.
38. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001;53:25-71.